Tredegar (TG) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
2 Dec, 2025Executive summary
Net income from ongoing operations was $9.2M ($0.26 per share) in Q3 2025, up from $0.2M ($0.01 per share) in Q3 2024; net income from continuing operations was $7.1M ($0.20 per share), reversing a loss of $3.4M in Q3 2024.
Net sales for Q3 2025 were $194.9M, a 33% increase from $146.1M in Q3 2024.
Consolidated EBITDA from ongoing operations reached $18.1M in Q3 2025, up from $6.8M in Q3 2024.
Both business units reported improved results; Aluminum Extrusions resolved manufacturing inefficiencies and PE Films continued strong cash generation.
Net debt declined to $36.2M at September 30, 2025, from $54.8M at year-end 2024.
Financial highlights
Diluted EPS from ongoing operations was $0.26 in Q3 2025, up from $0.01 in Q3 2024; diluted EPS from continuing operations was $0.20, compared to $(0.10) in Q3 2024.
For the first nine months of 2025, net sales reached $538.8M, up from $428.2M in the same period of 2024.
Gross profit margin improved to 16.0% in Q3 2025 from 12.4% in Q3 2024.
Cash flows from operations for the first nine months were $17.3M, up from $6.1M in the prior year; capital expenditures totaled $9.2M.
Net debt as of September 30, 2025, was $36.2M; total debt was $49.5M; cash and equivalents were $13.3M.
Outlook and guidance
Cost reduction opportunities are being evaluated, with benefits expected to begin in 2026.
Capital expenditures for 2025 are projected at $17M for Aluminum Extrusions and $2M for PE Films.
Management expects sufficient liquidity for at least the next 12 months, with $13.3M in cash and $72.5M available under the ABL Facility as of September 30, 2025.
Surface Protection volume growth in PE Films is expected to moderate for the remainder of the year.
Management remains cautious on net new order activity, especially in aluminum extrusions, due to ongoing tariff and market uncertainties.
Latest events from Tredegar
- 2025 saw robust earnings growth, improved leverage, and strong segment performance amid tariff challenges.TG
Q4 202511 Mar 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor, with strong governance focus.TG
Proxy Filing2 Dec 2025 - Virtual meeting on May 9, 2025, to vote on directors, pay, and auditor ratification.TG
Proxy Filing2 Dec 2025 - Net income and EBITDA fell in Q2 2025 as tariffs and inefficiencies pressured results.TG
Q2 20258 Oct 2025 - Improved Q3 results, Terphane sale, and lower leverage amid ongoing margin pressures.TG
Q3 202413 Jun 2025 - Q2 2024 net income rebounded to $8.8M with broad EBITDA gains and key regulatory decisions ahead.TG
Q2 202413 Jun 2025 - Net income jumped to $10.1M as Terphane sale and tariffs boosted results despite margin pressure.TG
Q1 20256 Jun 2025 - Tredegar posts strong EBITDA growth and sharp debt reduction, returning to profitability in 2024.TG
Q4 20245 Jun 2025